Label: VARDENAFIL tablet, orally disintegrating

Compound annual growth rate (CAGR) calculations suggest a 5–6% growth from 2023 to 2028, primarily propelled by: Expansion into emerging markets (Asia-Pacific, Latin America) Increased acceptance of generics, reducing patient costs Rise in over-the-counter product availability Technological innovations in formulation (e.g., fast-dissolving tablets) Regional variations could influence market share: North America is expected to be the dominant segment, but Asia-Pacific will witness the fastest growth, with a CAGR near 8%, due to higher prevalence and lower treatment access costs.

Manufacturing costs for vardenafil have declined due to economies of scale and global production.

How to Order

Patients should contact their healthcare provider for dose modification if they are not satisfied with the quality of their sexual performance with this drug, or in the case of an unwanted side effect. Vardenafil hydrochloride is a phosphodiesterase type 5 (PDE5) inhibitor approved primarily for erectile dysfunction (ED). It is marketed under brand names such as Levitra and Staxyn. Globally, the ED treatment market has valued approximately $4 billion in 2022. The segment including vardenafil accounts for roughly 20% of this market, with an estimated revenue of $800 million in 2022.

What should I do if I accidentally take too much vardenafil?

Key manufacturers include Bayer, Teva Pharmaceuticals, and Sun Pharma. The generic segment's share increased from 15% in 2015 to over 50% by 2022, driven by patent expirations and regional generics proliferation. Bayer's patent for Levitra expired in 2018, allowing generic manufacturers to enter multiple markets. This reduced prices by an estimated 40–60%, impacting branded sales. The expiration facilitated increased accessibility and expanded the patient base, especially in emerging markets. Generic production costs are estimated at $0.10–$0.15 per pill, compared to branded formulations at $1.00–$2.00, creating profit margins of 85–90% for generics.

Regulatory harmonization reduces approval timelines and cost, fostering quicker market entry.

5.3 Risk of Priapism

If taking potent or moderate inhibitors of CYP450 3A4, the dose should be adjusted as follows: Ritonavir: No more than 2.5 mg in a 72-hour period Indinavir, saquinavir, atazanavir, ketoconazole 400 mg daily, itraconazole 400 mg daily, clarithromycin: No more than 2.5 mg in a 24-hour period Ketoconazole 200 mg daily, itraconazole 200 mg daily, erythromycin: No more than 5 mg in a 24-hour period Safety and efficacy have not been established in patients younger than 18 years. This drug is not indicated for use in pediatric patients. This drug can be taken with or without food. The 10 mg orally disintegrating tablet (ODT) provides higher systemic exposure and is not interchangeable with the 10 mg film-coated tablets. The ODT tablet should be taken without liquid and immediately upon removal from the blister.

Medications & Supplements

Patients who require a lower or higher dose than 10 mg should be prescribed the film-coated tablets. Patients treated with alpha-blockers, who have previously used vardenafil film-coated tablets, may be switched to ODT tablets at the advice of their healthcare provider. Patients should stop use of PDE5 inhibitors, including this drug, and seek medical attention in the event of sudden loss of vision in one or both eyes, and decrease or loss of hearing. Symptoms related to postural hypotension may occur, appropriate countermeasures are recommended. Contact the prescribing physician if other antihypertensive drugs or new medications that may super p force 200mg interact with this drug are prescribed by another healthcare provider. Countries with streamlined approval processes, such as India and Brasil, enable faster revenue realization.

5.8 Hepatic Impairment

COGR surveys its member institutions throughout the year to gather essential data and insights on topics of particular interest to the academic research community, which helps to support COGR’s advocacy efforts. In addition to these policy topic surveys, COGR also has a Volunteer Survey, open year round, so that representatives from member institutions can note their areas of expertise and their interest in engaging in various volunteer opportunities with COGR. If you have any questions about an open survey, please contact memberservices@. The FDA has approved a new generic equivalent to Levitra for erectile dysfunction. Officials with the FDA have approved the Abbreviated New Drug Application (ANDA) for Alembic’s Vardenafil Hydrochloride Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.

Pulmonary Arterial Hypertension (Orphan)

The drug is indicated for the treatment of erectile dysfunction.1 According to Alembic, the approved ANDA is therapeutically equivalent to Bayer’s vardenafil hydrochloride (Levitra) tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.1 Vardenafil hydrochloride tablets were developed by GlaxoSmithKline and Bayer, and approved by the FDA in 2003.2 Vardenafil hydrochloride tablet have an estimated market size of $35 billion for 12 months ending June 2020, according to data obtained by Alembic.1 Alembic Pharmaceuticals Receives USFDA Final Approval for Vardenafil Hydrochloride Tablets, 2.5 mg (base), 5 mg (base), 10 mg (base), and 20 mg (base) [news release]. Some Branded Drugs Going Generic in 2018. Applies to the following strengths: 2.5 mg; 5 mg; 10 mg; 20 mg Initial dose: 10 mg orally once a day, as needed, approximately 60 minutes before sexual activity. Increase to 20 mg or decrease to 5 mg based on efficacy and tolerability. Maximum dose: 20 mg once a day Initial dose: 5 mg orally once a day Sexual stimulation is required for a response to treatment. Conversely, stringent regulations in the US and EU can delay launches, impacting short-term revenue but fostering long-term stability.

Further information

In the US, the final patent expiration occurred in 2020. The European patent expired in 2017, leading to a surge in generic imports. Patent cliffs across major markets significantly shifted revenue streams, transitioning from branded dominance to a generics-focused market. The drug's pharmacology fildena online remains stable with a half-life of 4–5 hours, allowing for flexible dosing. It competes with tadalafil (Cialis) and sildenafil (Viagra), which have similar efficacy but differ in duration and side effect profile.

Related Disease Conditions

Commercially, the ED market is expanding due to increasing prevalence related to aging populations and rising awareness. The global aging demographic is expected to increase ED prevalence from 10% to 30% in men aged 40–70. Market growth is driven by increased focus on sexual health, over-the-counter availability in some regions, and newer formulations improving patient adherence. The popularity of combination therapies and the rise of telemedicine further influence demand dynamics. Projection estimates forecast the ED market reaching over $6.5 billion globally by 2028, with vardenafil contributing approximately 15–20% of this value. Pricing policies vary, with government-mandated price caps in several markets influencing profit margins.

• Vardenafil 10 mg may be used by men over 18 years.
• The medication is not approved for use in women or children.
• May be contraindicated in patients with certain eye conditions.
• Use caution if you have a history of stroke.
• The drug’s chemical action involves improving blood flow.
• It is important to distinguish ED causes before treatment.
• Use only medications prescribed by a healthcare professional.
• Avoid combining with other erectile dysfunction medications.
• Keep medication out of sunlight and moisture.
• Seek emergency medical help for severe side effects.

For instance, India enforces prices 30–40% lower than international reference prices, reducing profit potential but increasing volume sales. Generic vardenafil dominates due to patent expiry, with leading players capturing over 60% of the accessible market: Teva Pharmaceuticals: Largest global producer with extensive distribution channels.

ICO Registered Website

Members located outside of Pennsylvania at the time of service or those who select Talk Therapy or Psychiatry services will receive care from a provider employed or contracted by Online Care Network II PC (OCN), also known as Amwell Medical Group. OCN is not an affiliate of UPMC. Limitations may apply for members of ASO plans that have opted out of coverage. Providers are not available to treat members who are in Puerto Rico. Privacy Statement & HIPAA Forms Terms & ConditionsCopyright 2026.

Consumer Information Use and Disclaimer

COGR also signed on to a broader research community letter led by ACE raising similar concerns. COGR provides this compilation of resources, many developed by COGR, explaining Facilities and Administrative (F&A/Indirect) costs, the importance of these… COGR brings together the nation’s top research institutions to advocate for sound policies, streamline compliance, and strengthen the U.S. research enterprise. COGR represents over 230 of the most research-intensive institutions in the U.S., providing expert policy advocacy and a strong voice on the financial and regulatory issues that impact research. Members gain access to timely insights, collaboration opportunities, and a national community of research leaders. Sun Pharma: Focused on Asian markets, rapidly expanding in Latin America.

• Vardenafil is ineffective without sexual arousal.
• It does not protect against sexually transmitted infections.
• Avoid excessive mental or physical exertion while on medication.
• Consult a healthcare professional if unsure about interactions.
• Don't take vardenafil if you've had recent heart attack.
• Use with caution if you have a bleeding disorder.
• Medication may cause a temporary drop in blood pressure.
• Avoid using if you have a known hypersensitivity.
• The pill should be taken as part of a treatment plan.
• Keep track of how you respond to the medication.

Mylan: Active in the US and Europe with competitive pricing.

• Some users may experience mild flickering vision episodes.
• The efficacy of vardenafil varies between individuals.
• The medication is available in various dosage forms.
• Always follow the specific instructions provided.
• Avoid taking vardenafil with high-fat meals to speed absorption.
• Do not take vardenafil if allergic to its ingredients.
• The drug may cause a temporary burning sensation.
• Use caution in patients with a history of priapism.
• Avoid combining vardenafil with certain herbal supplements.
• Consult your doctor about any ongoing health treatments.

Brand dominance persists in some regions, especially where patent protections remain valid or where consumer preference favors branded formulations. Innovation in delivery mechanisms (e.g., fast-dissolving tabs, new formulations) is limited but ongoing, primarily driven by generic manufacturers. Patent litigation or patent extensions delaying generic entry.

• The onset of vardenafil 10 mg is typically 30-60 minutes.
• It can last up to 4-5 hours in some users.
• Vardenafil is contraindicated with certain heart medications.
• Use caution if you have a history of hypotension.
• The tablet may cause mild gastrointestinal upset.
• Do not consume large amounts of alcohol when taking vardenafil.
• Inform your doctor if you experience sudden hearing loss.
• Use only as directed by your healthcare provider.
• Discontinue if you experience persistent erection issues.
• The medication does not increase sexual desire.

Competition from new drugs or alternative therapies.

Generic vs Brand

A time gel erectile dysfunction interval between dosing should be considered when administering this drug concomitantly with alpha-blockers. Patients taking alpha-blockers should not initiate vardenafil therapy with the orally disintegrating tablet. Initial dose: 5 mg orally once a day, as needed, approximately 60 minutes before sexual activity Comments: Sexual stimulation is required for a response to treatment. CrCl: 30 to 80 mL/min: No adjustment recommended. Comment: The orally disintegrating tablet (brand Staxyn) can be used in patients with mild, moderate or severe renal impairment.

Usual Geriatric Dose for:

Mild hepatic dysfunction (Child-Pugh A): No adjustment recommended. Moderate hepatic dysfunction (Child-Pugh B): 5 mg orally once a day, as needed, approximately 60 minutes before sexual activity. The maximum dose should not exceed 10 mg. Severe hepatic dysfunction (Child-Pugh C): Use should be avoided. Comment: The orally disintegrating tablets should not be used in patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic dysfunction.

Unser Haus